glp 1 eligibility If you're covered by the State Health Benefit Plan (SHBP) and take a weight-loss GLP-1 medication (like Wegovy or Zepbound), a change is coming. Starting February 1, 2026, SHBP will require these Eligibility criteria specified in GLP-1

The studies included analyses of clinical records and real-world databases tracking patients taking Novo Nordisk's Wegovy or Ozempic, Eli Lilly's Zepbound or Mounjaro, or older GLP-1 treatments

GLP-1 receptor agonists work by mimicking the naturally occurring hormone glucagon-like peptide-1, which slows gastric emptying, increases satiety, and reduces appetite

Survodutide impresses in phase 2 weight-loss trial [Internet] [cited 2024 Jan 31]

For someone starting at 300 pounds, the gap widens even further

Many insured patients discover their tier 3 copay plus coinsurance exceeds $200$300 monthly, making PlexusDx the more economical choice

Even in settings where clinical response to biologics is preserved, the presence of obesity provides a strong rationale for adjunctive metabolic interventions